Heuchel G, Hässler W
Z Gesamte Inn Med. 1976 Feb 1;31(3):61-5.
A comparison of the therapy, especially of the long-term recidivation prophylaxis of the myocardial infarction with acetyl salicylic acid and anticoagulants, on the basis of 314 observations allows of the following opinions: By means of the thrombocyte aggregation inhibitor acetyl salicylic acid an antithrombotic therapy and recidivation prophylaxis of good value can be performed. The application of acetyl salicylic acid is, concerning the course of the disease after the onset of the infarction and the frequency of recidivation, adequate to the treatment with classical anticoagulants. The practical performance of the long-term therapy with acetyl salicylic acid is significantly simplified for physician and patient compared with the application of anticoagulants. The daily dose lies uniformly at 1.5 g. There is no fear of acute haemorrhagic complications. As control only the occasional establishment of the Hb-value as well as of the time of haemorrhage is indicated. The only, however, very decisive disadvantage of the acetyl salicylic acid, the bad compatibility for the stomach, is certainly not abolished with the new drug "Micristin", but much diminished.
基于314例观察结果，对使用乙酰水杨酸和抗凝剂治疗心肌梗死，尤其是长期预防复发的疗效进行比较后，可得出以下观点：通过血小板聚集抑制剂乙酰水杨酸可进行具有重要价值的抗血栓治疗和复发预防。就梗死发作后的病程及复发频率而言，乙酰水杨酸的应用与经典抗凝剂治疗相当。与应用抗凝剂相比，乙酰水杨酸长期治疗的实际操作对医生和患者而言都显著简化。每日剂量统一为1.5克。无需担心急性出血并发症。作为对照，仅需偶尔测定血红蛋白值以及出血时间。然而，乙酰水杨酸唯一非常关键的缺点，即对胃的耐受性差，在新药“米克里斯汀”中虽未完全消除，但已大大减轻。
